InvestorsHub Logo
Followers 231
Posts 34993
Boards Moderated 1
Alias Born 11/19/2003

Re: None

Monday, 07/14/2014 11:24:53 PM

Monday, July 14, 2014 11:24:53 PM

Post# of 2206
Silenceworks 8: First patient dosed in Hep C clinical trial

analyst updates and more

I’m pleased to attach the latest edition of Silenceworks. As you can see, April to July has been a very significant period for Benitec:
The first patient was dosed in Benitec's TT-034 Hepatitis C clinical trial
Maxim and Shaw both initiated coverage of Benitec with ‘buy’ recommendations
Calimmune gained approval to commence dosing the second cohort of patients in their HIV clinical trial
and much more. To read Silenceworks 8, please use this link

https://apj3.smixexpress.com/express/clients/benitec/papers/Silenceworks_Issue_8_July_2014.pdf

Regards,

Carl Stubbings | Chief Business Officer

Benitec Biopharma Limited | F6A / 1-15 Barr Street | Balmain NSW 2041 Australia
ABN: 64068943662
t: (+61 2) 9555 6986 | m: (+61) 423666374|
e:cstubbings@benitec.com | w: www.benitec.com | Skype: carl-stubbings
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTC News